Biotech Values

[steveporsche]

Quote: " My predict from 1.5 years ago looks to have been substantially too conservative. At this point it looks like IFN-L gets to market well BEFORE the widespread use of any triple DAA therapy. Excluding the BMY 2DAAs, perhaps it even gets to market before any 2DAAs are approved for use with SOC."

I agree, and the take out price of $735m net of cash was a very bad joke.